OCEL: AI 评分 49/100 — AI 分析 (4月 2026)

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases. Their lead product, Zofin, is undergoing clinical trials for COVID-19 treatment and is derived from perinatal sources.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company developing biological therapeutics, primarily Zofin, for degenerative diseases. Zofin, derived from perinatal sources, is currently in Phase I/II clinical trials for COVID-19, positioning Organicell within the regenerative medicine sector alongside competitors like AMHV and ATHJF.

OCEL是做什么的？

Organicell Regenerative Medicine, Inc., founded in 2011 and headquartered in Miami, Florida, is a clinical-stage biopharmaceutical company dedicated to the development of biological therapeutics for treating degenerative diseases. Originally incorporated as Biotech Products Services and Research, Inc., the company rebranded to Organicell Regenerative Medicine, Inc. in June 2018 to better reflect its focus on regenerative medicine. The company's primary product candidate, Zofin, is an acellular, biologic therapeutic derived from perinatal sources. Zofin is manufactured to retain naturally occurring microRNAs without any additives or diluents. Currently, Zofin is undergoing Phase I/II clinical trials as a potential treatment for COVID-19. Beyond its therapeutic development, Organicell also provides education, advertising, and marketing services to medical, healthcare, anti-aging, and regenerative service providers. The company has established research collaborations, including an agreement with the Centers for Disease Control and Prevention (CDC) to investigate Zofin's anti-inflammatory and anti-infective properties in influenza models and an agreement with Oklahoma State University to assess Zofin's efficacy in treating respiratory diseases caused by viruses with pandemic potential.

OCEL的投资论点是什么？

Organicell Regenerative Medicine, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is approximately $0.02 billion, with a negative P/E ratio of -3.75, reflecting its current lack of profitability. The primary value driver is the potential success of Zofin in clinical trials, particularly its Phase I/II trial for COVID-19. Upcoming data releases from these trials will be critical catalysts. A gross margin of 81.6% indicates strong potential profitability if Zofin gains regulatory approval and achieves commercial success. However, the company's negative profit margin of -92.3% highlights the significant expenses associated with research and development. The stock's beta of 1.36 suggests higher volatility compared to the overall market. The company's success hinges on navigating the regulatory landscape and securing partnerships for manufacturing and distribution.

OCEL在哪个行业运营？

Organicell operates within the competitive biotechnology industry, focusing on regenerative medicine. The market for regenerative medicine is projected to experience substantial growth, driven by increasing demand for therapies addressing degenerative diseases and aging-related conditions. Companies like AMHV, ATHJF, EMMLF, GRAMF, and KMSTF also operate in this space, developing various regenerative therapies. Organicell's focus on perinatal-derived biologics differentiates it within the market. The industry is characterized by high research and development costs, stringent regulatory requirements, and a lengthy time-to-market for new therapies.

Biotechnology

Healthcare

OCEL有哪些增长机遇？

Zofin Clinical Trial Success: The successful completion of Phase I/II clinical trials for Zofin in treating COVID-19 could lead to regulatory approval and commercialization. The global market for COVID-19 therapeutics remains significant, although evolving with vaccination efforts. Positive trial results would significantly increase Organicell's valuation and attract potential partnerships. Timeline: Data readout expected in late 2026.
Expansion of Zofin to Other Indications: Organicell can explore Zofin's potential in treating other degenerative diseases beyond COVID-19. The regenerative medicine market for conditions like osteoarthritis, Alzheimer's disease, and cardiovascular diseases is substantial. Successful preclinical and clinical studies in these areas could broaden Zofin's market reach. Timeline: Preclinical studies ongoing, with potential clinical trials starting in 2027.
Strategic Partnerships and Licensing Agreements: Partnering with larger pharmaceutical companies for manufacturing, distribution, and commercialization of Zofin can accelerate its market penetration. Licensing agreements in specific geographic regions or for specific indications can generate revenue and reduce financial risk. Timeline: Ongoing discussions, with potential agreements in 2026-2027.
Government Grants and Funding: Securing government grants and funding for research and development can reduce Organicell's financial burden and support its clinical programs. Government agencies and foundations are increasingly investing in regenerative medicine research. Timeline: Ongoing applications, with potential awards in 2026.
Development of New Biologic Therapeutics: Expanding the pipeline with new biologic therapeutics targeting other degenerative diseases can diversify Organicell's product portfolio and reduce its reliance on Zofin. This requires investment in research and development and the acquisition of new technologies or intellectual property. Timeline: Research and development ongoing, with potential new product candidates in 2028.

Market capitalization of $0.02 billion reflects its small size and early stage of development.
Negative P/E ratio of -3.75 indicates the company is currently unprofitable.
Gross margin of 81.6% suggests strong potential profitability if products are successfully commercialized.
Profit margin of -92.3% highlights significant R&D expenses and lack of revenue from product sales.
Beta of 1.36 indicates higher volatility compared to the market average.

OCEL提供哪些产品和服务？

Develop biological therapeutics for degenerative diseases.
Focus on acellular, biologic therapeutics derived from perinatal sources.
Manufacture Zofin, a therapeutic retaining naturally occurring microRNAs.
Conduct Phase I/II clinical trials for Zofin to treat COVID-19.
Provide education, advertising, and marketing services to medical and healthcare providers.
Collaborate with the CDC to study Zofin's effectiveness against influenza.
Partner with Oklahoma State University to evaluate Zofin for respiratory diseases.

OCEL如何赚钱？

Develop and commercialize biological therapeutics for degenerative diseases.
Generate revenue through potential sales of Zofin, pending regulatory approval.
Provide education, advertising, and marketing services to healthcare providers.
Seek research and development funding through grants and partnerships.

Patients suffering from degenerative diseases, including COVID-19.
Medical and healthcare providers seeking regenerative medicine solutions.
Research institutions and government agencies interested in biological therapeutics.

Proprietary technology in deriving and manufacturing Zofin from perinatal sources.
Intellectual property protection for Zofin and its therapeutic applications.
Established research collaborations with the CDC and Oklahoma State University.
First-mover advantage in developing perinatal-derived biologics for specific indications.

什么因素可能推动OCEL股价上涨？

Upcoming: Data readout from Phase I/II clinical trials for Zofin in COVID-19 treatment expected in late 2026.
Ongoing: Potential for securing government grants and funding for research and development.
Ongoing: Progress in expanding Zofin's applications to other degenerative diseases.
Ongoing: Strategic partnership discussions with larger pharmaceutical companies.

OCEL的主要风险是什么？

Potential: Failure of Zofin in clinical trials.
Potential: Regulatory hurdles and delays in obtaining approvals.
Ongoing: Competition from established pharmaceutical companies with greater resources.
Ongoing: Financial constraints and the need for additional funding to support operations.
Ongoing: Risks associated with operating in the OTC market, including limited liquidity and disclosure.

OCEL的核心优势是什么？

Proprietary technology in perinatal-derived biologics.
Zofin in Phase I/II clinical trials for COVID-19.
Research collaborations with reputable institutions.
High gross margin potential (81.6%).

OCEL的劣势是什么？

Negative profit margin (-92.3%).
Limited revenue generation.
Reliance on the success of Zofin.
Small market capitalization.

OCEL有哪些机遇？

Expansion of Zofin to other degenerative diseases.
Strategic partnerships for manufacturing and distribution.
Government grants and funding for research.
Development of new biologic therapeutics.

OCEL面临哪些威胁？

Clinical trial failures.
Regulatory hurdles and delays.
Competition from established pharmaceutical companies.
Financial constraints and need for additional funding.

OCEL的竞争对手是谁？

American Healthcare Capital — Focuses on healthcare investments and acquisitions. — (AMHV)
Athersys Inc — Developing regenerative medicine therapies for various diseases. — (ATHJF)
Enzolytics Inc — Developing therapeutics for infectious diseases and cancer. — (EMMLF)
Geron Corporation — Developing telomerase inhibitors for cancer treatment. — (GRAMF)
Kimmeridge Energy Management Co — Investment firm with holdings in healthcare and other sectors. — (KMSTF)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Harry L. Leider FACPE,
Headquarters: Miami, US
Employees: 20
Founded: 2016

AI Insight

AI analysis pending for OCEL

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Organicell Regenerative Medicine, Inc. do?

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for the treatment of degenerative diseases. Its lead product candidate, Zofin, is an acellular, biologic therapeutic derived from perinatal sources and is currently in Phase I/II clinical trials for COVID-19. The company also provides education, advertising, and marketing services to medical and healthcare providers, and collaborates with research institutions to explore new therapeutic applications for its products.

What do analysts say about OCEL stock?

As of March 17, 2026, there is no readily available analyst consensus on OCEL stock due to its OTC listing and early stage of development. Key valuation metrics such as P/E ratio (-3.75) and profit margin (-92.3%) reflect the company's current lack of profitability. The primary growth consideration is the successful development and commercialization of Zofin, which is subject to clinical trial outcomes and regulatory approvals. Investors should conduct their own due diligence and consider the risks associated with investing in a small, OTC-listed biotechnology company.

What are the main risks for OCEL?

The main risks for Organicell Regenerative Medicine, Inc. include the potential failure of Zofin in clinical trials, regulatory hurdles and delays in obtaining approvals, competition from established pharmaceutical companies with greater resources, financial constraints and the need for additional funding, and risks associated with operating in the OTC market, including limited liquidity and disclosure. The company's reliance on the success of Zofin also poses a significant risk, as any setbacks in its development could negatively impact the company's valuation and prospects.